NCT01295814 - Efficacy Study of Adalimumab to Treat Interstitial Cystitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

July 31, 2013

Conditions

Interstitial Cystitis

Interventions

DRUG

Adalimumab

80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period

OTHER

inactive drug

80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period

Trial Locations (1)

Philip C. Bosch, MD, Escondido